Payer/KOL P&R Input to New Oncology Biologic Development Plan
ADVI conducted primary research with payer informant KOLs and secondary research to augment company knowledge and develop the “right questions” and TPPs.
In order to test a variety of potential TPPs with payers to define value, positioning, and clinical and economic benefits necessary to optimize P&R for a new oncology biologic – and gain payer insights on the evolving competitive landscape, including biosimilars – ADVI conducted primary research with payer informant KOLs and secondary research to augment company knowledge and develop the “right questions” and TPPs.
CEO insights
Related articles
Real analysis from people who’ve been there
Commercial Contracting Process, Evaluations, and Metrics
ADVI helped a client understand the different ways of looking at account performance, plus embed contracting metrics into the contracting process.
Launch Planning and Implementation Support for Novel Biologic
ADVI helped management design and execute a series of interlocking P&R and market access imperatives.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.